Treatment compositions

Abstract

Compositions for and methods of treating diseases related to oxidative stress are described.

We claim: 
     
         1 . A composition comprising at least one redox signaling agent (RXN) and a PPAR agonist. 
     
     
         2 . The composition of  claim 1 , wherein the PPAR agonist comprises a Free Fatty Acid (FFA). 
     
     
         3 . The composition of  claim 1 , wherein the PPAR agonist comprises an eicosanoid. 
     
     
         4 . The composition of  claim 1 , wherein the PPAR agonist comprises a thazolidinedione. 
     
     
         5 . The composition of  claim 1 , wherein the PPAR agonist comprises a fibrate. 
     
     
         6 . The composition of  claim 1 , wherein the PPAR agonist comprises a dual agonist. 
     
     
         7 . The composition of  claim 6 , wherein the dual agonist comprises aleglitazar. 
     
     
         8 . The composition of  claim 6 , wherein the dual agonist comprises muraglitazar. 
     
     
         9 . The composition of  claim 6 , wherein the dual agonist comprises tesaglitazar. 
     
     
         10 . The use of a composition comprising RXN and a PPAR agonist in the treatment of a PPAR-mediated disease. 
     
     
         11 . The use of  claim 10 , wherein the PPAR-mediated disease is diabetes mellitus. 
     
     
         12 . The use of  claim 11 , wherein the diabetes mellitus is type 1 diabetes. 
     
     
         13 . The use of  claim 11 , wherein the diabetes mellitus is type 2 diabetes. 
     
     
         14 . The use of  claim 10 , wherein the PPAR-mediated disease is obesity. 
     
     
         15 . The use of  claim 10 , wherein the PPAR-mediated disease is cancer. 
     
     
         16 . The use of a composition comprising at least one RXN in the treatment of cancer, comprising a first therapy which activates a PPAR pathway and at least one other agent wherein the at least one other agent does not activate a PPAR pathway. 
     
     
         17 . The use of  claim 16 , wherein the at least one other agent comprises radiation. 
     
     
         18 . The use of  claim 16 , wherein the at least one other agent comprises a chemotherapeutic agent. 
     
     
         19 . The use of a composition comprising at least one RXN in the treatment of cancer, comprising a first therapy which mobilizes Free Fatty Acids (FFAS) and at least one other agent wherein the at least one other agent does not mobilize FFAs. 
     
     
         20 . The use of  claim 19 , wherein the at least one other agent comprises radiation. 
     
     
         21 . A method of treating an oxidative stress related disorder comprising:
 administering a composition including at least one species selected from O 2 , H 2 , Cl 2 , OCl − , HOCl, NaOCl, HClO 2 , ClO 2 , HClO 3 , HClO 4 , H 2 O 2 , Na + , Cl − , H + , H − , OH − , O 3 , O 4 * − ,  1 O, OH* − , HOCl—O 2 * − , HOCl—O 3 , O 2 * − , HO 2 *, NaCl, HCl, NaOH, water clusters, or a combination thereof to a patient experiencing oxidative stress; and   treating the oxidative stress related disorder.   
     
     
         22 . A method of treating a reduced mitochondrial DNA disorder comprising:
 administering a composition including at least one species selected from O 2 , H 2 , Cl 2 , OCl − , HOCl, NaOCl, HClO 2 , ClO 2 , HClO 3 , HClO 4 , H 2 O 2 , Na + , Cl − , H + , H − , OH − , O 3 , O 4 * − ,  1 O, OH* − , HOCl—O 2 * − , HOCl—O 3 , O 2 * − , HO 2 *, NaCl, HCl, NaOH, water clusters, or a combination thereof to a patient experiencing the reduced mitochondrial DNA disorder;   increasing mitochondrial DNA density; and   treating the reduced mitochondrial DNA disorder.   
     
     
         23 . The method of  claim 22 , wherein the reduced mitochondrial DNA disorder is sacropenia, diabetes, Alzheimer's disease, Parkinson's disease, neurological disease, muscle loss due to aging, obesity, or cardiovascular disorders.